The NLRP3 inhibition may represent an optimal strategy to mitigate the impact of comorbidities associated with COVID-19 such as diabetes mellitus (109, 110), hypertension (111), and obesity (112, 113). The gene discussed is NLRP3; the disease is obesity due to melanocortin 4 receptor deficiency.